News
New partnership to boost research into vaccines for cancer
Trials into vaccines for cancer and wider diseases are expected to accelerate after the Government reached a historic agreement with a leading biopharmaceutical firm to bring revolutionary research to England. A memorandum of understanding has been
signed by Secretary of State for Health and Social Care, Steve Barclay, and the Germany-based company BioNTech, which previously developed a world-leading COVID-19 vaccine with Pfizer. The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. No 2 cancers are the same and mRNA vaccines will contain a genetic
blueprint to stimulate the immune system to attack cancer cells. Access to the trials will be through the Cancer
Vaccine Launch Pad, which is being developed by NHS England and Genomics England. The launch pad will help to rapidly identify large numbers of cancer patients who could be eligible for the trials and explore potential vaccines across multiple types of cancer. Trials for innovative treatments could start as early as autumn 2023. The partnership will aim to help patients with early- and late-stage cancers. If successfully developed, the cancer vaccines could become part of standard care.
Rapid rollout of lifechanging devices
Around eight in ten people with Type 1 diabetes now have access to life-changing technology, as a result of cost-effective deals secured for patients and rapidly rolled out by the NHS. Just over 200,000 patients are now using non-
invasive glucose monitoring devices (CGMs) that allow people to check their glucose levels more easily and regularly – up by a third (around 50,000) compared to the spring. This summer, the NHS announced patients with Type 1 diabetes would be eligible for continuous glucose monitors – after securing a deal to ensure they cost a similar price to flash monitors – and already almost two-thirds
of local NHS areas are offering these devices to patients. The newer wearable arm gadget sends information automatically to a mobile app and allows diabetes patients to always keep track of their glucose levels without having to scan or take a finger prick test. The latest figures show the NHS is going above its original target from 2019 to ensure 20% of people with Type 1 diabetes benefit from flash monitors. The NHS aims for all integrated care boards to be offering both monitors in 2023 and the wider rollout of this technology will help diabetes patients manage their condition better – reducing hospital admissions and diabetes complications.
Update on scarlet fever and invasive group A strep
Latest data from the UK Health Security Agency (UKHSA) continues to show scarlet fever and group A strep (GAS) infections remain high. So far this season (from 19 September to 1 January) there have been 35,616 notifications of scarlet fever. This compares to a total of 4,192 at the same point in the year during the last comparably high season in 2017 to 2018 – although cases in that season started to rise at a different point. In 2017 to 2018 there were 30,768 scarlet fever notifications overall across the year. Invasive group A strep (iGAS) infections
remain rare but are currently higher than we see in a typical year. So far this season, there have been 159 iGAS cases in children aged 1 to 4 compared to 194 cases in that age group across the whole year of the last comparably high season in 2017 to 2018. There have been 118 cases in children aged 5 to 9 years compared to 117 across the whole year of the last comparably high season in 2017 to 2018. The majority of iGAS cases continue to be in the over 45s. Sadly, so far this season, there have been 151 deaths across all age groups in England. This figure includes 29 children under 18 in England. In the 2017 to 2018 season, there were 355 deaths in total across the season, including 27 deaths in children under 18.
Wipe out infections, without wiping out your equipment.
Protect & Prevent with #PurpleTop
The first "Made in Britain" 2-in-1 cleaning & disinfectant wipe included in more than 600 manufacturers IFUs
Request Samples via
contact@pdi-emea.com February 2023 I
www.clinicalservicesjournal.com 11
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
